Literature DB >> 1954383

Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.

K Bhalla1, P Swerdlow, S Grant.   

Abstract

We have examined the effect of the ribonucleotide reductase inhibitors thymidine (dThd) and hydroxyurea (HU) on the metabolism and cytotoxicity of high concentrations (10 to 100 mumol/L) of cytosine arabinoside (Ara-C) in a deoxycytidine kinase-deficient, highly Ara-C-resistant human promyelocytic leukemic cell subline (HL-60/Ara-C). Administration of dThd or HU (0.5 to 3 mmol/L) in conjunction with high concentrations of Ara-C either sequentially or simultaneously lead to enhanced (and in some cases a supra-additive) inhibition of HL-60/Ara-C suspension culture growth and soft agar colony formation. In addition, exposure of cells to 0.5 mmol/L dThd or HU for 48 hours significantly increased the percentage of HL-60/Ara-C in S-phase. In contrast to previous studies involving low-dose Ara-C administration, we were unable to detect dThd- or HU-mediated increments in Ara-CTP formation in HL-60/Ara-C cells treated with high-dose Ara-C despite reductions in intracellular dCTP pools as great as 65%. However, dThd or HU did increase Ara-C incorporation into newly synthesized DNA. These studies show that administration of dThd or HU in conjunction with high concentrations of Ara-C results in an enhanced antiproliferative effect of Ara-C against Ara-C-resistant leukemic cells deficient in deoxycytidine kinase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1954383

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Mechanism of the antiviral action of 1-beta-D-arabinofuranosylcytosine on Borna disease virus.

Authors:  Romain Volmer; Jeffrey J Bajramovic; Urs Schneider; Sandra Ufano; Sylvie Pochet; Daniel Gonzalez-Dunia
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.

Authors:  Ping Chen; Josephine Aimiuwu; Zhiliang Xie; Xiaohui Wei; Shujun Liu; Rebecca Klisovic; Guido Marcucci; Kenneth K Chan
Journal:  AAPS J       Date:  2010-12-30       Impact factor: 4.009

3.  Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.

Authors:  T Szekeres; K Gharehbaghi; M Fritzer; M Woody; A Srivastava; B van't Riet; H N Jayaram; H L Elford
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Authors:  Joshua F Zeidner; Judith E Karp; Amanda L Blackford; B Douglas Smith; Ivana Gojo; Steven D Gore; Mark J Levis; Hetty E Carraway; Jacqueline M Greer; S Percy Ivy; Keith W Pratz; Michael A McDevitt
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

5.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Authors:  Judith E Karp; Francis J Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
Journal:  Leuk Res       Date:  2007-07-20       Impact factor: 3.156

6.  Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.

Authors:  May Levin; Michal Stark; Bluma Berman; Yehuda G Assaraf
Journal:  Cell Death Dis       Date:  2019-05-17       Impact factor: 8.469

7.  Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Authors:  Sean G Rudd; Nikolaos Tsesmetzis; Kumar Sanjiv; Cynthia Bj Paulin; Lakshmi Sandhow; Juliane Kutzner; Ida Hed Myrberg; Sarah S Bunten; Hanna Axelsson; Si Min Zhang; Azita Rasti; Petri Mäkelä; Si'Ana A Coggins; Sijia Tao; Sharda Suman; Rui M Branca; Georgios Mermelekas; Elisée Wiita; Sun Lee; Julian Walfridsson; Raymond F Schinazi; Baek Kim; Janne Lehtiö; Georgios Z Rassidakis; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Mats Heyman; Dan Grandér; Sören Lehmann; Thomas Lundbäck; Hong Qian; Jan-Inge Henter; Torsten Schaller; Thomas Helleday; Nikolas Herold
Journal:  EMBO Mol Med       Date:  2020-01-17       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.